MW Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute

By Steve Goldstein

Novo Nordisk reportedly will strike a deal with Hims & Hers.

Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Hims & Hers shares $(HIMS)$ rose 47% to $23.17 as Bloomberg News, citing a person familiar with the matter, reported that the two companies will announce a deal to sell weight-loss drugs on the Hims platform.

Neither company has confirmed the move, and it's unclear the terms.

An analyst at Citi, Daniel Grosslight, estimated Hims would have to sell 70% more branded subscriptions to offset the impact of ending "mass personalization" compounded GLP-1 drug making.

Novo Nordisk had sued Hims & Hers after the U.S. company announced a plan to sell an oral version of Novo's new weight-loss pill Wegovy. It has since shelved that plan as it also came under pressure from the Food and Drug Administration.

Novo Nordisk stock (DK:NOVO.B) (NVO) rose 1%, against a declining European stock market. Novo's stock is still down 23% as it struggles to fend off competition in the burgeoning weight-loss drug market, and as a study of a next-generation medication disappointed investors.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 09, 2026 05:45 ET (09:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.